22 August 2025 | Sydney, Australia – LTR Pharma Limited (ASX:LTP) today announced that SPONTAN® has achieved an 18-month shelf life under international pharmaceutical stability standards, a key milestone that strengthens the product’s commercial potential in the global erectile dysfunction market, forecast to reach US$6.0 billion by 2028. This achievement demonstrates the robustness of SPONTAN’s formulation, delivery device, and packaging system under standard storage conditions. The 18-month shelf life exceeds current requirements for the Company’s growing Australian pharmacy network and provides the stability foundation essential for international market entry and partnership discussions.
Highlights:
SPONTAN® achieves 18-month shelf life under ICH conditions, surpassing current commercial distribution requirements.
Confirms commercial-scale manufacturing and distribution capabilities across Australia.
Supports strategic discussions with leading pharmaceutical partners.
